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444The most promising approach to improve the specificity of prostate-specific antigen
(PSA) test relies on the measurement of different molecular isoforms of PSA in serum.
Currently, inmenwith a total PSA (tPSA) level between 2and 10 ng/mL,measurement
of %fPSA (free to total PSA ratio3100) is used as reflex testing to better distinguish be-
tween malignant and benign prostate disease. Recently, Beckman Coulter devel-
oped the prostate health index (PHI) and several studies suggested that this test
may improve the diagnostic ability of %fPSA.We performed a meta-analysis to eval-
uate the usefulness of PHI compared with %fPSA in the detection of prostate cancer
(PCa) at first biopsy in men with tPSA ‘‘gray’’ levels of 2–10 ng/mL. Data on sensitivity
and specificity were extracted from 8 eligible studies. Only observational studies
comparing the diagnostic ability of PHI and %fPSA in tPSA range of 2–10 ng/mL
were included. A total of 8 studies involving 2969 patients with a tPSA range of 2–
10 ng/mL undergoing first biopsy were included in this meta-analysis. Biopsy-
confirmed PCa was detected in 1287 (43.3%) men. Selected studies determined
both PHI and %fPSA as a reflex test. The areas under curve (AUCs) of PHI and
%fPSA were 0.74 (95% confidence interval [CI], 0.70–0.77) and 0.63 (95% CI, 0.58–
0.67), respectively. Meta-regression analysis confirmed the superiority of PHI which
showed, compared with %fPSA, a relative diagnostic odds ratio of 2.81 (95% CI,
2.19–3.6; P , 0.0001). In conclusion, PHI instead of %fPSA as a reflex test in men
with tPSA ‘‘gray’’ levels is a better predictor of positive first biopsy and can offer a
reduction in unnecessary biopsies. (Translational Research 2014;164:444–451)Abbreviations: AUC ¼ area under curve; CIs ¼ confidence intervals; DOR ¼ diagnostic odds
ratio; DRE ¼ digital rectal examination; FDA ¼ food and drug administration; fPSA ¼ freePSA;
HSROC ¼ hierarchical summary receiver-operator curves; PCa ¼ prostate cancer; PHI ¼ pros-
tate health index; PSA¼ prostate specific antigen; pPSA¼ p roPSA; p2PSA¼ [-2]proPSA; USPSTF
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Total studies identified=723 
Excluded at full text stage: 
not eligible: 8 
Excluded at abstract stage: 
Communications to
congresses: 24 
not available: 11 
not eligible: 9 
Excluded at title stage: 
irrelevant: 76 
narrative review, editorial, 
guidelines or commentary: 20 
Not published in English: 6 
519 removed
duplicates
162 unique articles
retrieved
60 articles requiring
abstract review
16 articles requiring
full text review
8 selected articles
Fig 1. Summary of literature search and selection of studies included.
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Prostate-specific antigen (PSA) has been widely used
in the management of patients with prostate cancer
(PCa). However, serum PSA levels showed limited
specificity particularly in a PSA range of 2–10 ng/
mL.1 Several approaches have been proposed to address
these limitations, including the measurement of PSA
molecular forms especially %fPSA. Anyway, the ability
to detect PCa at initial biopsy remains limited.2 Free
PSA (fPSA) comprises proPSAs (pPSAs), benign PSA
(BPSA), and intact PSA. Mikolajczyk et al3 reported
that pPSA is associated with cancer and BPSA with
benign diseases, whereas the association of intact PSA
is currently unknown. pPSA includes several truncated
forms that can be measured in serum by immunoas-
says.4 The [-2]proPSA (p2PSA) is the most cancer-
specific form of all, being preferentially expressed
in cancerous prostatic epithelium and significantly
increased in serum of men with PCa.2 During the past
2 years, 2 biomarkers have been approved by the US
Food and Drug Administration. These include p2PSA
as part of the prostate health index (PHI) by Beckman
Coulter, Inc, calculated by a mathematical formula
([-2][pPSA/fPSA) 3 sqrt (PSA)] combining PSA mo-
lecular forms.5 Currently, several studies suggested
that increased PHI levels seem to preferentially detect
patients with PCa.5-9
The hypothesis regarding the improvement in predict-
ing biopsy outcome of PHI compared with %fPSA is
inspiring, but till now, no consensus has been reached
on which is the best test recommended in clinical prac-
tice. At present, only one meta-analysis has been per-
formed10 to assess the usefulness of %[-2]proPSA and
PHI in PCa detection in the overall PSA range and in
the initial and subsequent biopsies. Our meta-analysis
is undertaken to evaluate the diagnostic value of PHI
compared with %fPSA in the ‘‘gray’’ PSA range of 2–
10 ng/mL in patients undergoing first biopsy.METHODS
Meta-analysis was performed in accordance with the
preferred reporting items from systematic reviews and
meta-analysis (PRISMA) adapted to the study of diag-
nostic test.11
Relevant published articles were identified by search-
ing computerized bibliographic systems (Pubmed, Web
of Science, Scopus, Cochrane Library, and Cancerlit)
from January 2009 to December 2013. A search strategy
was used that contained the following text words and
medical subject headings in their titles, abstracts, or
keyword lists: PSA testing (prostate health index, PHI,
tumor markers, p2PSA, sensitivity, specificity and per-
formance) and PCa detection (PCa diagnosis or biopsyoutcome). This literature search was complemented
with the review of 5 specialized journals in Urology
(European Urology, Journal of Urology, British Journal
of Urology, International Journal of Urology and Pros-
tate). The summary of literature search and selection
of studies included is shown in Fig 1.
All the studies were considered eligible for inclusion
if they met the following criteria:
1. original data;
2. study including at least 20 patients with PCa;
3. confirmation of PCa on transrectal ultrasound-
guided needle biopsy (minimum $6 cores)
4. serum levels of fPSA, tPSA, and p2PSA evaluated
by commercially available kits of Beckman Coul-
ter using Hybritech calibration;
5. tPSA included between 2 and 10 ng/mL;
6. sufficient data to allow us to calculate true positive
(TP), false negative (FN), false positive (FP) and
true negative (TN) values for PCa diagnosis;
7. blood was sampled before prostate manipulation
or biopsy and antiandrogen therapy;
8. the indication for biopsy was independent of the
PHI test result;
9. results were based on first biopsy;
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among men with tPSA levels between 2 and
10 ng/mL;
11. English language.
Studies with no usable data, lacking control groups,
bad in quality, receiving therapy, or underwent to digital
rectal examination (DRE) before samples were taken
were excluded.
Two of the authors (D.T. and C.M.), whowere blinded
to the journal, author, institution, and date of publica-
tion, independently reviewed each publication. Both
reviewers, separately, screened all titles and excluded
studies if obviously irrelevant and removed duplicate
citations.
To assess inter-rater consistency, an independent
reviewer also extracted data using the same criteria for
a random subset of articles (25%). The analysis of the
concordance between both researchers about the eligi-
bility of a studywas done by calculating the kappa index.
We assessed the quality of studies using the quality
assessment of studies of diagnostic accuracy (QUA-
DAS) included in systematic review checklist,12,13
which contains 14 items specifically developed to
assess the quality of primary studies of diagnostic
tests. Each itemwas scored as ‘‘yes,’’ ‘‘no,’’ or ‘‘unclear.’’
Data synthesis and analysis. Sensitivity and specificity
with their 95% confidence intervals (CIs) were
computed for both diagnostic markers in each study
and reported graphically on forest plots.
Data extraction showed a large heterogeneity in the
reporting of diagnostic accuracy measures: some
studies reported the diagnostic performance constrain-
ing the sensitivity at a high value, whereas others fixed
a priori the value of specificity; in some cases the pairs
of sensitivity and specificity were determined by look-
ing at the best combination of detection rate (sensitivity)
and FP rate. Occasionally, multiple pairs of sensitivity
and specificity were reported. This led to a large vari-
ability in the positivity thresholds that, additionally, in
some studies were not specified.
For such reasons, the average operating points (ie,
summary sensitivity and specificity) with the corre-
sponding 95% confidence regions were not computed
as recommended in the Cochrane Handbook for Sys-
tematic Reviews of Diagnostic Test Accuracy.14 On
the contrary, the summary Receiver operating character-
istics (ROC) curves for PHI and % fPSA were con-
structed using the hierarchical model proposed by
Rutter and Gatsonis.15 This approach, that accounts
for both within and between studies variation, models
the relationship between sensitivity and specificity by
using three parameters: (1) a proxy for positivity thre-
shold, measured on an underlying latent scale; (2) ameasure of accuracy defined as the logarithm of the
diagnostic odds ratio (DOR), which measures the ratio
between the odds of a positive result between diseased
and nondiseased subjects; (3) a scale parameter that
models the symmetry of the curve allowing test accu-
racy to vary with ‘‘threshold.’’ The first 2 are treated
as random effects (ie, study dependent), whereas the
scale parameter is considered fixed. The Hierarchical
summary receiver-operator curves (HSROC) parame-
terization is considered the most appropriate approach
when the variability in threshold is expected to be larger
than the variability in the accuracy.16
Diagnostic performance of each marker was thus
summarized using the area under curve (AUC) of the
summary ROC curves, restricted to observed FP rates
and normalized; the partial AUC was computed using
the estimates of the HSROC parameters. In case of sym-
metric curves, the DOR was also computed, as for sym-
metric curve the DOR does not depend on the specific
threshold.
The comparison between the 2 markers was under-
taken by using a meta-regression approach, treating
the type of test (PHI and %fPSA) as a dummy variable
and exploring its effect on the shape (symmetry) and po-
sition (accuracy) of the summary ROC curve.
The SAS statistical package, the Stata software (Sta-
taCorp, College Station, Texas), and the R language
were used for all the statistical analysis. A P value
,0.05 was used to denote statistical significance.RESULTS
Study characteristics and quality. In the literature
search, 723 articles were identified. Among these, 162
unique articles were retrieved. As shown in Fig 1, 16
articles required full-text review and 8 studies,
meeting the inclusion criteria, were finally included in
this meta-analysis. All these studies contain data on
both PHI and %fPSA. Of note, the study by Jansen
was performed on 2 distinct populations (Rotterdam
and Innsbruck) and was analyzed separately as 2
studies.
The results about the concordance between both re-
viewers had a kappa index of 0.88 (95% CI, 0.64–
1.00; P , 0.001).
The baseline characteristics of the selected studies are
shown in Table I including the type of population stud-
ied, age range of participants, size of each study, and the
sampling frame. In addition, tPSA range, percentage of
positive DRE, and biopsies were indicated. The crite-
rion used to establish the diagnostic accuracy of each
marker (high sensitivity, high specificity, and best com-
bination) is also shown together with the reported posi-
tivity thresholds. The existence of a large variability in
Table I. Characteristics of the studies included in the meta-analysis
Reference
Sampling
frame
Years of
recruitment
of patients Population Age of patients
tPSA range
(ng/mL)
Digital
rectal
examination
Number of
biopsies
Patients
with
cancer
Criterion for
reporting
diagnostic
accuracy
PHI positivity
threshold
(greater than)
%fPSA
positivity
threshold
(less than)
Ferro et al 201325 Single centre and
prospective
Not reported Referral 60.4 6 6
(Mean 6 SD)
2–10 19% Positive 300 108 (36%) Best combination 42.8 12%
Guazzoni et al 20117 Single centre and
prospective
2010 Referral 63.3 6 8.2
(Mean 6 SD)
2–10 Negative 268 107 (40%) High specificity 48.5 29%
Jansen et al 2010
Site 16
Retrospective 1994–1997 Screening and
not serial
66 (55–75)
Median (range)
2–10 Positive 405 226 (56%) High specificity Not reported Not reported
Jansen et al 2010
Site 26
Retrospective Started
in 1993
Screening and
not serial
69 (50–77)
Median (range)
2–10 Not reported 351 174 (50%) High specificity Not reported Not reported
Lazzeri et al 201326 Multicentre and
prospective
2011–2012 Referral 64.2 6 7.5
(Mean 6 SD)
2–10 18% Positive 646 264 (40%) Best combination 41.5 15%
Le et al 20105 Single centre and
prospective
2007 Screening and
consecutive
65 (Median) 2.5–10 Negative 63 26 (41%) High sensitivity Not reported Not reported
Loeb et al 201327 Multi-centre and
prospective
2003–2009 Selected $50 2–10 Negative 706 430 (48%) High sensitivity 35.0 Not reported
Ng et al 201328 Single centre and
retrospective
2008–2013 Referral 65.9 (50–79)
Mean (range)
4–10 Negative 230 21 (9%) High sensitivity 26.5 28%
Abbreviations: %fPSA, free to total PSA ratio 3100; PHI, prostate health index; tPSA, total prostate-specific antigen; SD, standard deviation.
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Table III. Quality assessment of studies of diagnostic accuracy included in systematic review questionnaire
Reference
Generalizability Clarity Validity
Q1 Q2 Q8 Q9 Q13 Q14 Q3 Q4 Q5 Q6 Q7 Q10 Q11 Q12
Ferro et al 201325 1 1 1 1 1 1 1 ? 1 1 1 1 1 Does not apply
Guazzoni et al 20117 1 1 1 1 1 1 1 ? 1 1 1 1 1 Does not apply
Jansen et al 2010 Site 16 2 1 1 1 1 1 1 ? 1 1 1 2 2 Does not apply
Jansen et al 2010 Site 26 2 1 1 1 1 1 1 ? 1 1 1 2 2 Does not apply
Lazzeri et al 201326 1 1 1 1 1 1 1 ? 1 1 1 1 1 Does not apply
Le et al 20105 2 1 1 2 1 2 1 ? 2 1 1 1 1 Does not apply
Loeb et al 201327 1 1 1 1 1 1 1 ? 1 1 1 1 1 Does not apply
Ng et al 201328 1 1 1 1 1 1 1 ? 1 1 1 1 1 Does not apply
Q1, spectrum of patients; Q2, selection criteria; Q8, index test; Q9, reference test; Q13, uninterpretable and/or intermediate test results; Q14,
withdrawals; Q3, reference test; Q4, time between reference test and index test; Q5, verification using reference test; Q6, reference standard
regardless of index test results; Q7, reference standard independent of the index test; Q10, blinding to reference test; Q11, blinding to index test;
Q12, same data available before interpretation of both index and reference tests.
1 Indicates ‘‘yes’’, 2 ‘‘no’’, and ?, ‘‘unclear.’’
Table II. Quality of the studies included in the meta-analysis according to the quality assessment of studies of
diagnostic accuracy included in systematic review questionnaire
Reference
Patients are
representative
of the question
Selection criteria
clearly described
Number of cores
per biopsy $10
Assays for the
measurement of
PHI are described Blinded
Ferro et al 201325 Yes Yes Yes Yes Yes
Guazzoni et al 20117 Yes Yes Yes Yes Yes
Jansen et al 2010 Site 16 Yes Yes No Yes No
Jansen et al 2010 Site 26 Yes Yes No Yes No
Lazzeri et al 201326 Yes Yes Yes Yes Yes
Le et al 20105 Yes Yes Not reported Yes Yes
Loeb et al 201327 Yes Yes Yes* Yes Yes
Ng et al 201328 Yes Yes Yes Yes Yes
*Median (range): 12 (6–34)
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from 12% to 29% for %fPSA is evident.
The quality evaluation of the selected studies was as-
sessed according to the quality assessment of studies of
diagnostic accuracy included in systematic review
scale12,13 (Tables II and III).
Before meta-analysis was performed, methodological
heterogeneity was evaluated. However, no studies were
excluded because of this cause.
Diagnostic performance of PHI compared with %fPSA as
a reflex test in the tPSA range of 2–10 ng/mL. Fig 2 shows
the sensitivity and the specificity along with their 95%
CIs for each individual study for both PHI and %fPSA
in the tPSA range of 2–10 ng/mL. Their funnel-like
shape, which reflects the inverse relation between
sensitivity and specificity, is sharpened by the
heterogeneity in the criterion used to report the
diagnostic performance. As expected, the I2 statistics
was significant (P , 0.001) for both the tests and the
proportion of heterogeneity because of a threshold
effect was 0.94 for PHI and 1.00 for %fPSA.Fig 3 displays the pairs of sensitivity and specificity in
the ROC space. For each individual study, a straight line
joins the results associated with the 2 tests. The corre-
sponding partial AUCs were 0.63 (95% CI, 0.58; 0.67)
for %fPSA and 0.74 (95% CI, 0.70–0.77) for PHI.
Both diagnostic tests resulted in a symmetric curve
(test for the shape coefficient not significant: P 5 0.57
and P 5 0.78, respectively). The DOR was estimated
to be 5.57 (95% CI, 4.20–7.40) for PHI and 2.01
(95% CI, 1.56–2.60) for %fPSA.
When comparing the 2 tests, no difference in shape
emerged. In particular, the increase in the 22log like-
lihood observed when removing the covariate for
shape was not significant (chi square 5 2.82; 2 df;
P . 0.05). On the contrary, PHI showed a significant
increase in the accuracy parameter leading to a rela-
tive DOR of 2.81 (95% CI, 2.19–3.6; P , 0.0001).
This means that the ratio between the odds of a pos-
itive result between diseased and nondiseased sub-
jects is at least doubled when using PHI instead of
%fPSA.
Fig 2. Forest plots of study results (sensitivity and specificity) for PHI and %fPSA as a predictor of prostate can-
cer. Squares represent study estimates, whereas lines represent the corresponding 95% CI obtained with the exact
binomial method. CI, confidence interval; TP, true positive; FP, false positive; FN, false negative; TN, true nega-
tive; PHI, prostate health index; %fPSA, free to total PSA ratio 3100.
Fig 3. ROC space showing the relationship between sensitivity and
specificity for PHI (black circles) and %fPSA (red diamonds). For
each study, the results of the 2 tests are joined by a straight line.
The curves represent the summary ROC curve associated with PHI
(black) and %fPSA (red). PHI, prostate health index; %fPSA, free
to total PSA ratio 3100. For interpretation of the references to color
in this figure legend, the reader is referred to the web version of this
article.
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Current clinical practice has been driven largely by
thewidespread use of PSA, allowing for unnecessary bi-
opsies and detection of many cases of indolent PCa.
Recent U.S. preventive services task force17 recom-
mends against PSA-based screening for PCa in all agegroups, highlighting the need for novel clinical useful
biomarkers.
The interest in more specific biomarkers encouraged
the development of new test improving clinical
outcome. Several studies have indicated that reflex tests
based on PSA isoforms can improve cancer detection in
men with tPSA levels between 2 and 10 ng/mL. In
particular, it has been widely accepted that a low
%fPSA is a useful test to reduce the number of unnec-
essary biopsies.18 However, it is now known that fPSA
fraction is composed of at least 3 different types of
enzymatically inactive PSA: BPSA, intact inactive
PSA, and pPSA, of which BPSA and pPSA are the
best characterized. In patients with PCa, serum pPSA
comprised primarily a truncated form of pPSA that
contains a proleader peptide consisting of only 2
([-2]pPSA) rather than the usual 7 amino acids
([-7]pPSA).19 Thus, serum pPSAs gained attention as
a potentially specific form of fPSA that may help over-
come the current limitations of %fPSA, reducing the
highest number of unnecessary biopsies. On the basis
of substantial evidence for the role of [-2]pPSA in early
PCa detection, Beckman Coulter Inc developed a math-
ematical algorithm incorporating [-2]pPSA, tPSA,
and fPSA for use in patients with PSA levels of
2–10 ng/mL with a nonsuspicious prostate on DRE.
This meta-analysis is the first study that compares the
published data on the clinical usefulness of PHI
comparedwith%fPSA in subjects undergoing first pros-
tate biopsy with PSA levels in the 2–10 ng/mL. The re-
sults of this meta-analysis showed that the use of PHI
compared with %fPSA can improve the detection of
PCa in men who have PSA levels of 2–10 ng/mL. The
AUCs obtained by the HSROC analysis were 0.74 for
PHI and 0.63 for %fPSA, suggesting a better ability of
PHI in PCa detection. Although both tests showed a
Translational Research
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different criteria used to derive the diagnostic perfor-
mance, the symmetry of the corresponding summary
ROC curves allowed to compare the 2 tests also in terms
of DORs. DOR values showed that the odd ratio of pos-
itive results between patients with cancer and without
cancer is about 3-fold greater for PHI than for %fPSA
in patients with tPSA levels included between 2 and
10 ng/mL. Of note, in all 8 selected studies in the
same study population PHI and %fPSAwere equally as-
sayed, so recruitment strategy or population characteris-
tics were not likely causes of differences in diagnostic
performance of the two tests.
An increasing number of patients are being diagnosed
with potentially low-risk, clinically insignificant can-
cers. In these patients, active surveillance has been pro-
posed as an alternative treatment strategy with the aim
of reducing the risk of radical prostatectomy side ef-
fects. However, we currently lack an ideal definition
of indolent PCa, and circulating biomarkers could be a
promising tool to identify patients harboring aggressive
disease.
Unfortunately, at present only few studies evaluated
the usefulness of PHI as a predictor of aggressive
PCa,8,20 impeding to perform meta-analysis. However,
Filella and Gimenez10 reported a critical analysis
showing that PHI may distinguish low- and high-risk
PCa. Further studies are required to better address this
issue.
This study has some limitations because of a very
high heterogeneity of the cutoffs used in the 8 eligible
studies included in this meta-analysis. In particular, as
shown in Table I, sensitivity and specificity are reported
differently among selected studies and information
about best cutoffs was not shown in about 50% of the
primary studies. Therefore, our meta-analysis was not
able to obtain data on pooled specificity about PHI, to
recommend an optimal cutoff value, and to quantify
missed cancers and avoided biopsies. To these aims a
more homogeneous criterion in reporting diagnostic ac-
curacy may be recommended in future reports.
Within specific PCa detection plan, a cost-benefit
analysis needs to be carried out to quantify whether
the extra costs of a PHI test with its corresponding
reduced numbers of biopsies will offer a net saving to
the health care provider. Such an analysis was recently
performed,21 suggesting that PSA plus PHI was a less
costly diagnostic strategy to detect PCa compared
with the PSA test alone. Taking into account that the
cost of %fPSA is clearly higher than PSA alone and
PHI can be expected to reduce false negative tests, the
use of PHI instead of %fPSA as a reflex test in tPSA
range of 2–10 ng/mL may decrease the global costs
and disutility related to the prostate biopsy procedure.In conclusion, our results suggested that PHI in pa-
tients with ‘‘gray’’ values of tPSA may be a better pre-
dictor of positive biopsy compared with %fPSA.
Filella and Gimenez10 reported in overall PSA range
and initial and subsequent biopsies that PHI increases
the specificity in PCa detection.
Several differences exist between our results and
those reported in Filella and Gimenez.10 From a meth-
odological perspective, our meta-analysis did not esti-
mate the summary pair of sensitivity and specificity
but rather we derived a summary ROC curve allowing
to compare the 2 markers along the whole range of
sensitivity and specificity pairs. This choice was moti-
vated by the large inconsistency in the threshold used
that could lead to a misleading interpretation of the
pooled results.22
Moreover, differently from Filella and Gimenez,10
our results focused on the PSA range (2–10 ng/mL)
with the highest overlap of benign and malignant pa-
thology, addressing the potential usefulness of PHI
compared with %fPSA as a reflex test.
Therefore, the use of PHI can offer a reduction in un-
necessary biopsies, whereas maintaining a high cancer
detection rate. However, given PCa heterogeneity, in
later years efforts to increase diagnostic accuracy
focused on a combination of biomarkers. Promising
results have been obtained by the combination of Pros-
tate cancer antigen 3 (PCA3) and v-ets erythroblastosis
virus E26 oncogene homolog (TMPRSS2-ERG) gene
fusions23 and with prostate health index (PHI).24
Furthermore, more studies are needed to define the
optimal PHI cutoff value and to evaluate the ability of
PHI in the discrimination of indolent and aggressive
PCa. Finally, worthy of further attention is the potential
improvement in diagnostic performance of the combi-
nation of PHI with other biomarkers.REFERENCES
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